By Counterforce Health Team in Ilaris (canakinumab) —

How to Get Ilaris (Canakinumab) Covered by Blue Cross Blue Shield in New York: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Ilaris Approved by Blue Cross Blue Shield in New York

Blue Cross Blue Shield plans in New York cover Ilaris (canakinumab) for Still's disease and periodic fever syndromes when strict prior authorization criteria are met. First step: Have your rheumatologist complete BCBS's formulary exception form with detailed documentation of failed therapies (NSAIDs, steroids, DMARDs, preferred biologics). If denied, you have 4 months to file an external appeal with NY Department of Financial Services, which has overturned Ilaris denials when medical necessity is well-documented. Most approvals require proof of inadequate response to standard treatments and specialist prescribing.

Table of Contents

  1. Understanding Blue Cross Blue Shield Coverage for Ilaris
  2. Reading Your Denial Letter
  3. Fixing Common Issues Before Appealing
  4. First-Level Internal Appeal Strategy
  5. Requesting a Peer-to-Peer Review
  6. New York External Appeal Process
  7. Medical Necessity Letter Template
  8. Tracking Your Appeal and Escalation
  9. Maximizing Your Win Rate
  10. If Your Appeal Fails: Next Steps
  11. Costs and Financial Assistance
  12. FAQ

Understanding Blue Cross Blue Shield Coverage for Ilaris

Ilaris (canakinumab) is a high-cost specialty biologic that requires prior authorization from all Blue Cross Blue Shield plans in New York. The medication costs approximately $20,000-$23,000 per dose, making it one of the most expensive treatments for autoinflammatory diseases.

Coverage at a Glance

Requirement What It Means Where to Find It
Prior Authorization Required before dispensing BCBS formulary or provider portal
Formulary Status Usually non-preferred/tier 4-5 Plan formulary PDF
Step Therapy Must try preferred biologics first Medical policy DRUG.00057
Specialist Required Rheumatologist or immunologist PA form requirements
Age Restrictions ≥2 years for sJIA, adults for AOSD FDA labeling criteria
Diagnosis Codes M06.1 (AOSD), M08.2x (sJIA) ICD-10 requirements

New York BCBS Entities

New York has several Blue Cross Blue Shield entities with slightly different policies:

  • Empire BlueCross BlueShield/Anthem (commercial and Medicaid)
  • Highmark Blue Cross Blue Shield (Western and Northeastern NY)

Each uses similar criteria but may have different forms and submission processes. Always verify your specific plan's requirements through your member portal or provider directory.

Reading Your Denial Letter

When Blue Cross Blue Shield denies Ilaris coverage, the denial letter will specify the exact reason. Common denial codes include:

Medical Necessity Denials:

  • "Not medically necessary for the member's condition"
  • "Clinical criteria not met per medical policy"
  • "Insufficient documentation of disease severity"

Step Therapy/Formulary Denials:

  • "Member must try preferred alternatives first"
  • "Prior authorization required for non-formulary drug"
  • "Step therapy protocol not completed"

Administrative Denials:

  • "Missing required clinical documentation"
  • "Prescriber not in network or lacks specialty credentials"
  • "Quantity exceeds approved limits"
Critical: Note the date of the denial letter. This starts your appeal timeline clock. In New York, you have 4 months from the final internal appeal denial to request an external review.

Fixing Common Issues Before Appealing

Before launching a formal appeal, check if your denial can be resolved quickly:

Missing Documentation

  • Lab results: Current inflammatory markers (ESR, CRP, ferritin)
  • Imaging: Joint X-rays or MRI showing active disease
  • Specialist notes: Rheumatology consultation confirming diagnosis

Coding Issues

  • ICD-10 codes: Ensure M06.1 (AOSD) or M08.2x (sJIA) is documented
  • Prescriber specialty: Verify rheumatologist or immunologist is listed
  • Site of care: Confirm if drug will be dispensed by specialty pharmacy

Prior Therapy Documentation

Many denials occur because the insurer can't verify you've tried required step-therapy drugs. Gather records showing:

  • NSAIDs: Specific drugs, doses, duration, and reason for discontinuation
  • Corticosteroids: Prednisone doses and inability to taper
  • DMARDs: Methotrexate or leflunomide trials with outcomes
  • Preferred biologics: Any TNF inhibitors or IL-6 blockers tried

First-Level Internal Appeal Strategy

Timeline and Process

  • Deadline: Usually 180 days from denial date for commercial plans
  • Decision time: BCBS must respond within 30 days (72 hours for urgent cases)
  • Who can appeal: Patient, prescriber, or authorized representative

Required Components

  1. Completed appeal form (available on your BCBS member portal)
  2. Copy of original denial letter
  3. Medical necessity letter from prescriber (see template below)
  4. Supporting clinical documentation
Tip: Submit appeals via certified mail or secure portal with delivery confirmation. Keep copies of everything.

Requesting a Peer-to-Peer Review

Before or during your appeal, request a peer-to-peer review where your prescribing physician speaks directly with BCBS's medical director.

How to Request

  1. Call BCBS provider services (number on your ID card)
  2. Ask for utilization management department
  3. Request peer-to-peer review for Ilaris denial
  4. Provide member ID, prescriber name, and denial reference number

Preparation Checklist for Your Doctor

  • Review your complete treatment history
  • Have current lab values and imaging available
  • Prepare 3-5 key talking points about medical necessity
  • Know specific contraindications to formulary alternatives

Many denials are overturned during peer-to-peer calls when the prescriber can explain the clinical rationale directly.

New York External Appeal Process

If your internal appeal is denied, New York's robust external appeal system provides a second chance through the Department of Financial Services (DFS).

Eligibility and Timeline

  • Deadline: 4 months from final internal appeal denial
  • Standard decision: 30 days for most cases
  • Expedited decision: 72 hours for urgent medical needs
  • Cost: Up to $25 (waived for financial hardship/Medicaid)

Required Forms

  1. New York State External Appeal Application
  2. Comprehensive Physician Attestation Form
  3. Copy of all denial letters
  4. Complete medical records supporting the request

When to Request Expedited Review

DFS will expedite your external appeal if:

  • Delaying Ilaris would seriously jeopardize your health
  • You're currently on the medication and interruption is dangerous
  • Your treating physician certifies that waiting poses an imminent threat
Success Rate: New York external appeals for specialty drugs have approximately 55-61% success rates when well-documented, especially for medical necessity cases.

Medical Necessity Letter Template

Your prescriber should include these elements in their medical necessity letter:

Header Information

Patient: [Full Name], DOB: [Date], Member ID: [Number]
Prescriber: [Name], NPI: [Number], Specialty: Rheumatology
Drug Request: Ilaris (canakinumab) 150mg/mL, [dose] subcutaneous every 4 weeks
Diagnosis: Adult-Onset Still's Disease (ICD-10: M06.1)

Clinical Background

  • Brief summary of diagnosis, onset, and current symptoms
  • Disease severity markers (fever frequency, joint count, functional impact)
  • Current inflammatory markers and imaging findings

Treatment History

Failed Therapies (include dates, doses, outcomes):

  • NSAIDs: [specific drugs tried, side effects or lack of efficacy]
  • Corticosteroids: [prednisone doses, inability to taper below X mg]
  • DMARDs: [methotrexate trial - dose, duration, reason for discontinuation]
  • Biologics: [any TNF inhibitors or IL-6 blockers - specific outcomes]

Rationale for Ilaris

  • Why formulary alternatives are inappropriate or contraindicated
  • Expected clinical benefit based on mechanism of action
  • Supporting literature (FDA labeling, ACR/EULAR guidelines)
  • Planned monitoring and safety measures

Medical Necessity Statement

"In my medical judgment, all formulary alternatives have been tried and failed, are contraindicated, or are expected to be ineffective for this patient's refractory Still's disease. Ilaris is medically necessary to control systemic inflammation and prevent organ damage."

Tracking Your Appeal and Escalation

Appeal Log Template

Keep a detailed record of all communications:

Date Action Contact Reference # Next Step Deadline
[Date] Submitted appeal BCBS Appeals Dept [Number] Await decision [30 days]
[Date] Peer-to-peer call Dr. [Name] [Reference] Follow up [1 week]

When to Escalate

Contact these resources if your appeal stalls:

Community Health Advocates: 888-614-5400 (free help for NY residents) NY Department of Financial Services: File complaint if BCBS violates timelines Your State Representatives: For systemic issues with plan policies

Maximizing Your Win Rate

Guideline Citations

Include these authoritative sources in your appeal:

  • FDA prescribing information for approved Still's disease indication
  • ACR/EULAR guidelines supporting IL-1 blockade in refractory cases
  • Specialty society position statements on autoinflammatory diseases

Document Contraindications

Clearly state why each formulary alternative is inappropriate:

  • TNF inhibitors: History of serious infections, heart failure, or malignancy
  • IL-6 inhibitors: Liver dysfunction, neutropenia, or GI perforation risk
  • Methotrexate: Renal impairment, alcohol use, or pulmonary toxicity

Functional Impact Evidence

Include objective measures of disease impact:

  • Disability questionnaires (HAQ, CHAQ for children)
  • Work/school absences due to flares
  • Emergency department visits for uncontrolled symptoms
  • Quality of life scores before and during flares

If Your Appeal Fails: Next Steps

Alternative Coverage Options

  1. Formulary alternatives: Consider anakinra (daily IL-1 blocker) or tocilizumab (IL-6 blocker)
  2. Clinical trials: Search ClinicalTrials.gov for canakinumab studies
  3. Compassionate use: Contact Novartis for expanded access program

Plan Changes

  • Open enrollment: Switch to a plan with better Ilaris coverage
  • Employer benefits: Ask HR about formulary differences between plan options
  • Medicaid: Explore eligibility if income qualifies

For persistent denials despite strong medical evidence:

  • Patient advocacy organizations: Contact Still's disease foundations
  • Legal aid: Some attorneys specialize in insurance coverage disputes
  • State insurance commissioner: File formal complaints for bad faith denials

Costs and Financial Assistance

Manufacturer Support

Ilaris Companion Program: Offers copay assistance and case management support for eligible patients. Contact at ilaris.com or through your prescriber.

Foundation Grants

  • Patient Access Network Foundation
  • HealthWell Foundation
  • Good Days (formerly Chronic Disease Fund)

State Programs

New York residents may qualify for:

  • Medicaid (expanded eligibility)
  • Essential Plan (for incomes 138-200% of federal poverty level)
  • Child Health Plus (for children)
From our advocates: We've seen patients successfully appeal Ilaris denials by emphasizing the "steroid-sparing" benefit when they couldn't taper prednisone below 10-15mg daily. This approach resonates with medical directors who understand long-term steroid complications. Always quantify your steroid dependence in appeals.

FAQ

How long does Blue Cross Blue Shield PA take in New York? Standard prior authorization decisions are made within 72 hours of receiving complete clinical documentation. Urgent requests are decided within 24 hours.

What if Ilaris is non-formulary on my plan? Request a formulary exception through your BCBS member portal or have your prescriber submit the exception form with detailed medical necessity documentation.

Can I request an expedited appeal? Yes, if your physician certifies that delaying treatment would seriously jeopardize your health. Expedited appeals are decided within 72 hours.

Does step therapy apply if I failed treatments outside New York? Yes, but you must provide documentation of previous treatment failures, including dates, doses, and specific reasons for discontinuation.

What happens if I'm hospitalized during the appeal? Hospital cases often qualify for expedited review. Have your inpatient team contact BCBS utilization management immediately for urgent authorization.

Can I continue current treatment while appealing? Some plans provide temporary coverage during appeals for medications you're already taking. Check your specific plan's transition policies.

Counterforce Health helps patients, clinicians, and specialty pharmacies turn insurance denials into successful appeals through evidence-based strategies and payer-specific workflows. Our platform analyzes denial patterns and generates targeted rebuttals that speak directly to each plan's criteria, helping you navigate complex prior authorization requirements more effectively.

Getting Ilaris approved by Blue Cross Blue Shield in New York requires persistence and thorough documentation, but the state's strong external appeal system provides meaningful recourse when internal appeals fail. With proper preparation and the right clinical evidence, many patients successfully obtain coverage for this life-changing medication.

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Always consult with your healthcare provider and insurance plan for specific coverage determinations. Coverage policies and appeal procedures may change; verify current requirements with your specific BCBS plan.

Sources & Further Reading

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.